TAK - FDA Approves Takeda's Eohilia As First Oral Treatment For Inflammed Esophagus | Benzinga
Monday, the FDA approved Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) Eohilia (budesonide oral suspension), the first and only FDA-approved oral therapy for people 11 years and older with eosinophilic esophagitis (EoE), a chronic, immune-mediated, inflammatory disease localized in the esophagus, a tube through which the food reaches the stomach for further digestion.
It will be available in convenient 2 mg/10 mL single-dose stick packs by the end of February.
Eohilia is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older with EoE.